NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $10.47 +0.09 (+0.87%) Closing price 04:00 PM EasternExtended Trading$10.42 -0.06 (-0.53%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About CorMedix Stock (NASDAQ:CRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CorMedix alerts:Sign Up Key Stats Today's Range$10.30▼$10.6450-Day Range$7.93▼$12.7952-Week Range$3.61▼$13.85Volume404,281 shsAverage Volume872,280 shsMarket Capitalization$635.29 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company OverviewCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More… Remove Ads CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 31% of companies evaluated by MarketBeat, and ranked 807th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 8.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.70% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in CorMedix has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.70% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in CorMedix has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.72 News SentimentCorMedix has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for CorMedix this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for CRMD on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Stock News HeadlinesCorMedix Inc. (NASDAQ:CRMD) Receives $15.67 Consensus Target Price from AnalystsMarch 12 at 2:11 AM | americanbankingnews.comCorMedix (NASDAQ:CRMD) Now Covered by Analysts at Leerink PartnersMarch 10, 2025 | americanbankingnews.comDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement from Elon any day now … Thousands of government jobs could be replaced … By a new form of AI. Recently perfected by Musk and his team at xAI.March 14, 2025 | Weiss Ratings (Ad)CorMedix (CRMD) to Release Earnings on TuesdayMarch 10, 2025 | americanbankingnews.comLeerink Partners Initiates Coverage of CorMedix (CRMD) with Outperform RecommendationMarch 8, 2025 | msn.comCorMedix initiated with an Outperform at LeerinkMarch 7, 2025 | markets.businessinsider.com3 Value Stocks Backed by World’s Largest Activist Hedge FundFebruary 26, 2025 | investing.comCormedix (NASDAQ:CRMD) Stock Quotes, Forecast and News SummaryFebruary 21, 2025 | benzinga.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $8.10 at the start of the year. Since then, CRMD shares have increased by 28.3% and is now trading at $10.3890. View the best growth stocks for 2025 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) issued its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. The firm earned $11.46 million during the quarter, compared to the consensus estimate of $11 million. When did CorMedix's stock split? Shares of CorMedix reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are CorMedix's major shareholders? CorMedix's top institutional shareholders include Vanguard Group Inc. (5.57%), Elliott Investment Management L.P. (4.73%), Geode Capital Management LLC (2.30%) and Northern Trust Corp (0.84%). Insiders that own company stock include Myron Kaplan, Erin Mistry and Elizabeth Hurlburt. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR). Company Calendar Last Earnings10/30/2024Today3/14/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$19.00 Low Stock Price Target$12.00 Potential Upside/Downside+55.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax Margin-387.73% Return on Equity-79.21% Return on Assets-64.68% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.60 Sales & Book Value Annual Sales$12.26 million Price / Sales51.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book8.07Miscellaneous Outstanding Shares60,677,000Free Float57,522,000Market Cap$626.49 million OptionableOptionable Beta1.53 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:CRMD) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.